De Motu Cordis
De Motu Cordis is a clinical stage pharmaceutical company based in Brisbane, Australia, dedicated to developing innovative emergency treatment solutions for life-threatening conditions. Founded by Professor John Fraser, the company focuses on creating faster, needle-free drug delivery devices, particularly for anaphylaxis and other emergencies, with a mission to deliver life-saving medicine faster when every second counts.
Industries
Nr. of Employees
small (1-50)
De Motu Cordis
Patents
Products
Needle-free dry powder inhaler for emergency epinephrine delivery
An investigational dry powder inhaler designed to deliver epinephrine via the pulmonary route for rapid treatment of anaphylaxis and other emergency indications.
Needle-free dry powder inhaler for emergency epinephrine delivery
An investigational dry powder inhaler designed to deliver epinephrine via the pulmonary route for rapid treatment of anaphylaxis and other emergency indications.
Services
Design and execution support for Phase 1 clinical studies and associated PK evaluations for inhaled therapies.
Development of dry powder formulations and API particle engineering to optimize pulmonary absorption and product stability.
Formative human factors studies to evaluate ease-of-use and inform device design suitable for non-medically trained users.
Coordination with GMP manufacturers and CDMOs to produce clinical trial supply for device and formulation combinations.
Regulatory planning and engagement with authorities for drug-device combination products, including preparation for pre-IND interactions.
Management and expansion of patent portfolios covering device designs, formulations and platform technologies across multiple jurisdictions.
Design and execution support for Phase 1 clinical studies and associated PK evaluations for inhaled therapies.
Development of dry powder formulations and API particle engineering to optimize pulmonary absorption and product stability.
Formative human factors studies to evaluate ease-of-use and inform device design suitable for non-medically trained users.
Coordination with GMP manufacturers and CDMOs to produce clinical trial supply for device and formulation combinations.
Regulatory planning and engagement with authorities for drug-device combination products, including preparation for pre-IND interactions.
Management and expansion of patent portfolios covering device designs, formulations and platform technologies across multiple jurisdictions.
Expertise Areas
- Inhalation drug delivery
- Dry powder inhaler development
- Formulation and particle engineering
- Drug-device combination development
Key Technologies
- Dry powder inhaler (DPI) technology
- Pulmonary delivery / inhalation pharmacokinetics
- Particle engineering for inhaled APIs
- Drug-device combination platforms
News & Updates
In April 2025, Professor John Fraser AO, Founder and Chief Medical Officer of DMC, presented at the Food Allergy Fund Summit in New York, sharing progress on DMC’s Epinephrine Inhaler.
Professor John Fraser outlined the latest ICU care innovations at Cleveland Clinic Abu Dhabi during JPM Week 2025.
De Motu Cordis was featured in a two-page article in the Courier Mail on March 15, 2025.
The company has grown its IP portfolio to 28 patents, protecting its innovations in emergency medicine and inhaler technology.
Professor Fraser received the Officer of the Order of Australia for his contributions to medicine and critical care research.
DMC commends ARS Pharma’s FDA approval of Neffy®, a needle-free intranasal epinephrine device for anaphylaxis.
In April 2025, Professor John Fraser AO, Founder and Chief Medical Officer of DMC, presented at the Food Allergy Fund Summit in New York, sharing progress on DMC’s Epinephrine Inhaler.
Professor John Fraser outlined the latest ICU care innovations at Cleveland Clinic Abu Dhabi during JPM Week 2025.
De Motu Cordis was featured in a two-page article in the Courier Mail on March 15, 2025.
The company has grown its IP portfolio to 28 patents, protecting its innovations in emergency medicine and inhaler technology.
Professor Fraser received the Officer of the Order of Australia for his contributions to medicine and critical care research.
DMC commends ARS Pharma’s FDA approval of Neffy®, a needle-free intranasal epinephrine device for anaphylaxis.